CAR-T Will Transform the Treatment of Malignant Diseases, But Challenges Remain in Selection, Logistics, and Toxicity
Interview:
CAR-T therapy is evolving rapidly, and we have only seen the beginning of this revolution in cancer treatment. Julian Hamfjord, Consultant Clinical Oncologist at the lymphoma section of Oslo University Hospital, shares his insights in this interview.
Relateret indhold
Brænder du for at skrive?
Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk
Send mail til redaktionen